AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 21.05 percent. This is a 7.69 percent increase over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $17.084 million which beat the analyst consensus estimate of $5.824 million by 193.31 percent. This is a 133.29 percent increase over sales of $7.323 million the same period last year.